- US500 and US100 slightly lose at the beginning of the session
- US Dollar (USD) one of the stronger currencies today
- US bond yields fall to 4.20%
The last day on Wall Street starts in the red. Indexes lose slightly at the opening of the cash session, but it should be noted that the quotations are currently at historical highs. The weaker sentiment in the stock market is also supported by the strengthening dollar. USD gains by 0.3%, and in most currency pairs between 0.3-0.4%, and even up to 0.6% in the case of NZD, AUD, and SEK. Meanwhile, yields on 10-year US bonds lose from the level of 4.21%.
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile appUSDIDX index gains over 0.30% and is approaching the key zone around 104,000. This is the second strong session in a row for the dollar, which is starting to exert stronger pressure on the stock market. Source: xStation 5
US500
The US500 index has been moving very dynamically upwards in recent weeks. Along the way, practically since the beginning of 2024, we have not experienced any significant correction. Looking at the chart, one can notice an almost parabolic upward movement. A correction in the indexes would be justified at this moment. However, looking at the market behavior, which finds reasons for growth in each publication, such a correction is hard to predict unequivocally.
Source: xStation 5
Company News
FedEx (FDX.US) gains as much as 8.70% despite mixed results in Fiscal Quarter 3 (FQ3) and a narrowed outlook for Fiscal Year 2024. This surge was attributed to cost-cutting in its Express business and improved margins in FQ3. The Express segment outperformed expectations with a 2.5% operating margin. The company’s overall adjusted operating margin increased to 6.2%. FedEx revised its FY2024 profit guidance to $17.25 - $18.25 per share and announced a new $5 billion share repurchase program.
Ocugen (OCGN.US) gains as much as 17% after a federal appeals court ruling that upheld a lower court's decision against shareholders' claims. These shareholders had accused the biotech company of misleading investors regarding its COVID-19 vaccine, Covaxin, specifically about obtaining emergency-use authorization from the U.S. Food and Drug Administration. The U.S. Court of Appeals for the Third Circuit rejected these claims, stating that the investors couldn't prove any point where Ocugen misrepresented its engagement with the FDA. The court emphasized that all relevant details were accessible to any reasonable investor.
Nike (NKE.US) shares fell by 8% following a revenue outlook that projected minimal growth. Despite exceeding FQ3 earnings expectations, Nike forecasted about 1% growth in FY2024 revenue and a low single-digit decline in the first half of fiscal 2025, mainly due to challenges in overseas markets.
Lululemon Athletica (LULU): dips over 18% after announcing a first-quarter outlook that was below market expectations. The company projected Q1 revenue of $2.18B - $2.20B and EPS of $2.35 - $2.40, both below consensus estimates. The full-year revenue expectation was set at $10.7B - $10.8B, slightly below the consensus.
Reddit (RDDT.US) shares fell by 8% following their debut, which had initially seen a 48% surge. The stock quotations showed strong initial performance, but the decline followed on the subsequent trading day.
Tesla (TSLA.US) shares declined by 3% amid reports of the company reducing electric car production at its China plant due to slowing EV sales growth.
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.